AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Atara Biotherapeutics Inc (NASDAQ:ATRA)
10.1 USD
+0.290 2.956%Sponsored Reports
Loading...
| Previous Close (in USD) | 9.81 |
|---|---|
| Change | +0.290 2.956% |
| 52 W H/L (in USD) | 39.500/6.500 |
| EBITDA (in USD) | -162.125M |
| PE Ratio | -- |
| Volume | 82077 |
| Diluted Eps TTM | -25.32 |
| Total Assets (in USD) | 165.504M |
|---|---|
| Total Liabilities (in USD) | 264.735M |
| Revenue TTM (in USD) | 62.387M |
| Cash (in USD) | 25.987M |
| Market Cap (in USD) | 73.840 M |
| Revenue Per Share TTM | 12.263 |
| Gross Profit TTM (in USD) | 63.573M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Dividend Paid
Atara Biotherapeutics Inc
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
2380 Conejo Spectrum Street, Thousand Oaks, CA, United States, 91320
805 623 4211
Employees: 165
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Pascal Touchon D.V.M. | Pres, CEO & Director | 1963 |
| 2. | Mr. Utpal Koppikar M.B.A. | Exec. VP & CFO | 1971 |
| 3. | Mr. K. Amar Murugan | Sr. VP & Gen. Counsel | 1975 |
| 4. | Dr. Jakob Dupont M.D. | Exec. VP and Global Head of R&D | 1965 |
| 5. | Ms. Charlene Banard | Chief Technical Officer | 1963 |
| 6. | Dr. Anhco Nguyen | Chief Scientific Officer | 1973 |
| 7. | Eric Hyllengren | VP of Investor Relations & Fin. | NA |
| 8. | Kerry Beth Daly | Head of Corp. Communications | NA |
| 9. | Ms. Amie Krause | Chief People Officer | NA |
| 10. | Mr. Joseph Newell | Exec. VP | 1970 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-2.260 2.133% | 104.27 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-1.680 1.573% | 108.27 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
-55.695 12.446% | 391 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
-4.445 0.622% | 711 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Income Before Tax | -276.111M | -228.29M | -340.095M | -306.605M | -290.964M |
| Minority Interest | - | - | - | - | - |
| Net Income | -276.126M | -228.302M | -340.141M | -306.62M | -290.976M |
| Selling General Administrative | 50.908M | 71.553M | 78.801M | 64.402M | 79.584M |
| Gross Profit | -0.313M | 49.005M | 20.34M | -9.867M | -8.105M |
| Reconciled Depreciation | 4.879M | 5.653M | 9.345M | 8.332M | 7.07M |
| Ebit | -269.276M | -280.513M | -340.462M | -309.052M | -295.681M |
| Ebitda | -264.447M | -330.75M | -331.117M | -300.72M | -288.611M |
| Depreciation And Amortization | 4.829M | -50.237M | 9.345M | 8.332M | 7.07M |
| Operating Income | -269.276M | -280.513M | -340.462M | -309.052M | -295.681M |
| Other Operating Expenses | 277.849M | 344.086M | 360.802M | 309.052M | 295.681M |
| Interest Expense | 5.285M | 1.986M | 9.712M | 10.779M | 11.787M |
| Tax Provision | 0.006M | 0.012M | 0.046M | 0.015M | 0.012M |
| Interest Income | 4.797M | 1.986M | 0.367M | 2.447M | 4.717M |
| Net Interest Income | 0.944M | 1.986M | 0.367M | 2.447M | 4.717M |
| Income Tax Expense | 0.015M | 0.012M | 0.046M | 0.015M | 0.012M |
| Total Revenue | 8.573M | 63.573M | 20.34M | 3.552M | 0M |
| Total Operating Expenses | 268.963M | 344.086M | 360.802M | 309.052M | 295.681M |
| Cost Of Revenue | 8.886M | 14.568M | 11.38M | 9.867M | 8.105M |
| Total Other Income Expense Net | -6.835M | 52.223M | 0.367M | 2.447M | 4.717M |
| Net Income From Continuing Ops | -290.248M | -228.302M | -340.141M | -306.62M | -290.976M |
| Net Income Applicable To Common Shares | - | -228.302M | -340.141M | -306.62M | -290.976M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 165.504M | 376.42M | 468.127M | 588.12M | 342.942M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 6.184M | 10.308M | 12.567M | 21.364M | 13.883M |
| Total Liab | 264.735M | 249.78M | 188.513M | 125.781M | 52.161M |
| Total Stockholder Equity | -99.231M | 126.64M | 279.614M | 462.339M | 290.781M |
| Other Current Liab | 48.53M | 50.405M | 44.905M | 40.343M | 5.733M |
| Common Stock | 0.011M | 0.01M | 0.009M | 0.008M | 0.006M |
| Capital Stock | 0.011M | 0.01M | 0.009M | 0.008M | 0.006M |
| Retained Earnings | -1969.15M | -1693.024M | -1464.722M | -1124.581M | -817.961M |
| Good Will | - | - | - | - | - |
| Other Assets | 0M | 7.018M | 3.567M | 14.33M | 1.767M |
| Cash | 25.987M | 92.942M | 106.084M | 200.404M | 74.317M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 142.226M | 78.916M | 105.786M | 82.901M | 36.743M |
| Current Deferred Revenue | 77.833M | 8M | 40.76M | 33.455M | 21.466M |
| Net Debt | 31.885M | -21.238M | -80.566M | -187.363M | -60.181M |
| Short Term Debt | 12.179M | 13.64M | 2.753M | 1.985M | 1.581M |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 57.872M | 71.704M | 25.518M | 13.041M | 14.136M |
| Other Stockholder Equity | 1870.112M | 1821.721M | 1744.695M | 1586.616M | 1108.516M |
| Property Plant Equipment | - | 6.3M | 79.939M | 50.517M | 54.176M |
| Total Current Assets | 101.869M | 295.08M | 384.621M | 523.273M | 272.992M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | 25.884M | 149.877M | 264.984M | 300.255M | 184.792M |
| Net Receivables | 34.108M | 40.221M | 0.986M | 1.25M | - |
| Long Term Debt | - | - | - | - | - |
| Inventory | 9.706M | 1.586M | - | - | - |
| Accounts Payable | 3.684M | 6.871M | 17.368M | 7.118M | 7.963M |
| Accumulated Other Comprehensive Income | -0.204M | -2.067M | -0.368M | 0.296M | 0.22M |
| Non Currrent Assets Other | 4.844M | 7.018M | 3.567M | 2.027M | 1.767M |
| Non Current Assets Total | 63.635M | 81.34M | 83.506M | 64.847M | 69.95M |
| Capital Lease Obligations | 57.872M | 71.704M | 25.518M | 15.026M | 15.717M |
| Long Term Debt Total | - | - | - | - | 0.244M |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Investments | 165.14M | 112.384M | 32.838M | -116.215M | 66.031M |
| Total Cashflows From Investing Activities | - | 202.956M | 22.258M | -120.728M | 60.459M |
| Total Cash From Financing Activities | 2.01M | 53.084M | 103.944M | 427.574M | 188.786M |
| Net Income | -276.126M | -228.302M | -340.141M | -306.62M | -290.976M |
| Change In Cash | -67.101M | -14.39M | -94.32M | 126.087M | 13.619M |
| Begin Period Cash Flow | 93.088M | 107.478M | 201.798M | 75.711M | 62.092M |
| End Period Cash Flow | 25.987M | 93.088M | 107.478M | 201.798M | 75.711M |
| Total Cash From Operating Activities | -192.977M | -270.43M | -220.522M | -180.759M | -235.626M |
| Depreciation | 4.829M | 5.653M | 9.345M | 8.332M | 7.07M |
| Other Cashflows From Investing Activities | - | 94.765M | - | - | 0.161M |
| Dividends Paid | - | 0.623M | 1.244M | 1.521M | 6.695M |
| Change To Inventory | -8.12M | -1.586M | 3.343M | -1.252M | -1.586M |
| Sale Purchase Of Stock | -0.094M | -0.623M | -1.244M | -1.521M | -6.695M |
| Other Cashflows From Financing Activities | -0.107M | 2.352M | 7.989M | 8.036M | 14.045M |
| Capital Expenditures | 1.223M | 4.193M | 10.58M | 4.513M | 5.733M |
| Change In Working Capital | 15.341M | -61.468M | 52.584M | 63.685M | -4.148M |
| Other Non Cash Items | 12.456M | -40.151M | 2.035M | 1.535M | 1.035M |
| Free Cash Flow | -194.2M | -274.623M | -231.102M | -185.272M | -241.359M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Total Stock Mkt Idx Inv | 1 month ago | 120258 |
| 2. | Vanguard Institutional Extnd Mkt Idx Tr | 1 month ago | 54473 |
| 3. | Fidelity Extended Market Index | 1 month ago | 25277 |
| 4. | Bridgeway Ultra-Small Company Market | 2 months ago | 14000 |
| 5. | BlackRock Small Cap Index V.I. I | 8 months ago | 10470 |
| 6. | Fidelity Enhanced Small Cap ETF | 3 weeks ago | 10014 |
| 7. | Fidelity VIP Disciplined Small Cap Init | 2 months ago | 9631 |
| 8. | Nationwide Multi-Cap Portfolio R6 | 6 months ago | 9061 |
| 9. | Fidelity Total Market Index | 1 month ago | 8132 |
| 10. | BlackRock Extended Equity Market K | 2 months ago | 7707 |
| 11. | Fidelity Series Total Market Index | 1 month ago | 6323 |
| 12. | T. Rowe Price Extended Equity Market Idx | 1 month ago | 4664 |
| 13. | NT Ext Equity Mkt Idx Fd - NL | 2 months ago | 3967 |
| 14. | NT Ext Equity Mkt Idx Fd - L | 2 months ago | 3542 |
| 15. | Northern Trust Extended Eq Market Idx | 2 months ago | 3542 |
| 16. | NT Ext Equity Mkt Idx Fd - DC - NL - T2 | 2 months ago | 3196 |
| 17. | Spartan Extended Market Index Pool E | 1 month ago | 2997 |
| 18. | Vanguard Balanced Index Inv | 1 month ago | 2595 |
| 19. | Spartan Total Market Index Pool E | 1 month ago | 2507 |
| 20. | PGIM Quantitative Solutions US Micro Cap | 2 months ago | 2500 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | EcoR1 Capital, LLC | 2 months ago | 468938 |
| 2. | Redmile Group, LLC | 2 months ago | 452270 |
| 3. | Citadel Advisors Llc | 2 months ago | 260480 |
| 4. | Bank of America Corp | 2 months ago | 203627 |
| 5. | Vanguard Group Inc | 2 months ago | 180715 |
| 6. | Millennium Management LLC | 2 months ago | 176053 |
| 7. | Vestal Point Capital LP | 2 months ago | 124677 |
| 8. | TANG CAPITAL MANAGEMENT LLC | 2 months ago | 75196 |
| 9. | Renaissance Technologies Corp | 2 months ago | 67734 |
| 10. | BlackRock Inc | 5 months ago | 61145 |
| 11. | Geode Capital Management, LLC | 2 months ago | 46720 |
| 12. | Centiva Capital LP | 2 months ago | 43403 |
| 13. | Staley Capital Advisers Inc | 2 months ago | 40000 |
| 14. | FMR Inc | 2 months ago | 25061 |
| 15. | State Street Corp | 2 months ago | 22353 |
| 16. | Morgan Stanley - Brokerage Accounts | 2 months ago | 16189 |
| 17. | Bridgeway Capital Management, LLC | 2 months ago | 14000 |
| 18. | JPMorgan Chase & Co | 2 months ago | 1370 |
| 19. | Wells Fargo & Co | 2 months ago | 1251 |
| 20. | Tower Research Capital LLC | 2 months ago | 752 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Related Articles
Loading...
